Pharmacyclics (PCYC) Releases Quarterly Earnings, Beats Expectations By $0.28 EPS
Pharmacyclics (NASDAQ:PCYC) announced its earnings results on Thursday. The company reported $0.95 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.67 by $0.28, American Banking News reports. The company had revenue of $123.60 million for the quarter, compared to the consensus estimate of $85.69 million.
Several analysts have recently commented on the stock. Analysts at Roth Capital raised their price target on shares of Pharmacyclics to $166.00 in a research note on Thursday, February 13th. On a related note, analysts at Zacks reiterated a “neutral” rating on shares of Pharmacyclics in a research note on Monday, January 27th. They now have a $142.00 price target on the stock. Finally, analysts at Nomura initiated coverage on shares of Pharmacyclics in a research note on Wednesday, January 8th. They set a “buy” rating on the stock. Four equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $146.93.
Shares of Pharmacyclics (NASDAQ:PCYC) traded up 2.75% during mid-day trading on Thursday, hitting $142.68. The stock had a trading volume of 1,124,943 shares. Pharmacyclics has a 52-week low of $71.85 and a 52-week high of $145.30. The stock’s 50-day moving average is $131.2 and its 200-day moving average is $122.. The company has a market cap of $10.517 billion and a P/E ratio of 55.23.
Pharmacyclics, Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.